Timber Pharmaceuticals, Inc.
TMBR · AMEX
12/31/2022 | 12/31/2021 | 12/31/2020 | 1/31/2020 | |
|---|---|---|---|---|
| Revenue | $83 | $296 | $454 | $325 |
| % Growth | -71.9% | -34.8% | 39.8% | – |
| Cost of Goods Sold | $13,302 | $6,150 | $1,501 | $3,383 |
| Gross Profit | -$13,219 | -$5,854 | -$1,047 | -$3,058 |
| % Margin | -15,892.4% | -1,979.4% | -230.8% | -942% |
| R&D Expenses | $13,302 | $6,150 | $15,104 | $3,383 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $6,017 | $5,387 | $4,060 | $587 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$83 | -$591 | -$454 | $0 |
| Operating Expenses | $19,235 | $10,946 | $18,711 | $587 |
| Operating Income | -$19,235 | -$10,650 | -$20,212 | -$3,645 |
| % Margin | -23,125.9% | -3,601.2% | -4,453.8% | -1,122.6% |
| Other Income/Exp. Net | -$136 | -$19 | $5,132 | -$46 |
| Pre-Tax Income | -$19,372 | -$10,669 | -$15,080 | -$3,690 |
| Tax Expense | $8 | -$30 | $38 | -$0 |
| Net Income | -$19,379 | -$10,639 | -$15,118 | -$3,690 |
| % Margin | -23,299% | -3,597.5% | -3,331.3% | -1,136.7% |
| EPS | -9.19 | -13.15 | -48.15 | -29.31 |
| % Growth | 30.1% | 72.7% | -64.3% | – |
| EPS Diluted | -9.19 | -13.15 | -48.15 | -29.31 |
| Weighted Avg Shares Out | 2,108 | 809 | 314 | 126 |
| Weighted Avg Shares Out Dil | 2,108 | 809 | 314 | 126 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $16 | $817 | $0 |
| Interest Expense | $228 | $16 | $4,417 | $0 |
| Depreciation & Amortization | $77 | $273 | $2,435 | $172 |
| EBITDA | -$19,158 | -$10,377 | -$17,777 | -$46 |
| % Margin | -23,032.8% | -3,509% | -3,917.3% | -14% |